Analyst Ratings For Bioverativ (NASDAQ:BIVV)
Today, Royal Bank of Canada raised its price target on Bioverativ (NASDAQ:BIVV) to per share.
Some recent analyst ratings include
- 1/18/2018-Credit Suisse Group Reiterated Rating of Neutral .
- 10/23/2017-Piper Jaffray Companies Reiterated Rating of Overweight .
- 10/6/2017-Morgan Stanley Reiterated Rating of Underweight.
- 9/20/2017-Argus Upgrade from a “Hold ” rating to a ” Buy” rating.
- On 8/9/2017 Brian S Posner, Director, bought 1,000 with an average share price of $59.19 per share and the total transaction amounting to $59,190.00.
- On 8/7/2017 Louis J Paglia, Director, bought 2,000 with an average share price of $59.70 per share and the total transaction amounting to $119,400.00.
- On 6/28/2017 Diantha Duvall, Insider, sold 818 with an average share price of $60.47 per share and the total transaction amounting to $49,464.46.
- On 5/30/2017 Alexander J Denner, Director, bought 90,000 with an average share price of $55.93 per share and the total transaction amounting to $5,033,700.00.
- On 5/26/2017 Louis J Paglia, Director, bought 2,000 with an average share price of $57.76 per share and the total transaction amounting to $115,520.00.
- On 5/24/2017 Brian S Posner, Director, bought 2,000 with an average share price of $53.86 per share and the total transaction amounting to $107,720.00.
Recent Trading Activity for Bioverativ (NASDAQ:BIVV)
Shares of Bioverativ closed the previous trading session at with 62.999298095703125 shares trading hands.
